Alex Thompson
Stock Analyst at Stifel
(4.64)
# 254
Out of 5,182 analysts
41
Total ratings
65.71%
Success rate
24.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Buy | $70 → $92 | $71.27 | +29.09% | 3 | Mar 18, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $47 → $72 | $69.00 | +4.35% | 2 | Mar 13, 2026 | |
| ANAB AnaptysBio | Maintains: Buy | $56 → $85 | $51.82 | +64.03% | 3 | Mar 5, 2026 | |
| CLDX Celldex Therapeutics | Reiterates: Buy | $58 → $68 | $34.25 | +98.54% | 1 | Feb 26, 2026 | |
| ALMS Alumis | Initiates: Buy | $44 | $24.98 | +76.14% | 1 | Feb 25, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $5 | $2.80 | +78.57% | 1 | Feb 25, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $254 → $256 | $240.29 | +6.54% | 4 | Dec 11, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,028 → $1,248 | $805.38 | +54.96% | 5 | Dec 11, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $90.15 | -27.90% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $38.78 | -35.53% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $14.22 | +54.71% | 1 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $55 | $88.07 | -37.55% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $14.29 | +151.92% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $38.90 | +54.24% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $17.22 | +300.70% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $4.17 | -76.02% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $14.28 | +180.11% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $28.28 | +20.23% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.29 | +2,458.14% | 1 | Dec 14, 2022 |
Spyre Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $70 → $92
Current: $71.27
Upside: +29.09%
Oruka Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $47 → $72
Current: $69.00
Upside: +4.35%
AnaptysBio
Mar 5, 2026
Maintains: Buy
Price Target: $56 → $85
Current: $51.82
Upside: +64.03%
Celldex Therapeutics
Feb 26, 2026
Reiterates: Buy
Price Target: $58 → $68
Current: $34.25
Upside: +98.54%
Alumis
Feb 25, 2026
Initiates: Buy
Price Target: $44
Current: $24.98
Upside: +76.14%
Palisade Bio
Feb 25, 2026
Initiates: Buy
Price Target: $5
Current: $2.80
Upside: +78.57%
Ascendis Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $254 → $256
Current: $240.29
Upside: +6.54%
argenx SE
Dec 11, 2025
Maintains: Buy
Price Target: $1,028 → $1,248
Current: $805.38
Upside: +54.96%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $90.15
Upside: -27.90%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $38.78
Upside: -35.53%
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $14.22
Upside: +54.71%
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $88.07
Upside: -37.55%
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $14.29
Upside: +151.92%
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $38.90
Upside: +54.24%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $17.22
Upside: +300.70%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $4.17
Upside: -76.02%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $14.28
Upside: +180.11%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $28.28
Upside: +20.23%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.29
Upside: +2,458.14%